Table 3.
Results of per-protocol analysis (N = 37)
| T0 median (range) | T1 median (range) | median difference* (95% CI) | P | rϕ | ||
|---|---|---|---|---|---|---|
| Balance performance | ||||||
| STEO sway path (mm) | IG | 628 (477 – 1339) | 616 (420 – 1261) | -76 (-141 – -17) | 0.018 | 0.56 |
| CG | 572 (326 – 928) | 578 (319 – 809) | -6 (-52 – 50) | 0.841 | 0.05 | |
| P | 0.049 | 0.327 | 0.049 | |||
| STEC sway path (mm) | IG | 1290 (735 – 4661) | 1486 (804 – 4885) | -32 (-205 – 142) | 0.717 | 0.09 |
| CG | 1466 (649 – 3089) | 1342 (607 – 2736) | 39 (-115 – 160) | 0.809 | 0.06 | |
| P | 0.781 | 0.408 | 0.659 | |||
| MSEO sway path (mm) | IG | 1755 (1255 – 2440) | 1667 (1058 – 3216) | -204 (-442 – 178) | 0.214 | 0.41 |
| CG | 1510 (844 – 2701) | 1303 (711 – 2266) | -204 (-367 – 2) | 0.056 | 0.51 | |
| P | 0.311 | 0.059 | 1.000 | |||
| MSEO duration (sec) | IG | 30 (1 – 30) | 30 (18 – 30) | 1 (0 – 7) | 0.051 | 0.49 |
| CG | 30 (11 – 30) | 30 (7 – 30) | 0 (0 – 2) | 0.500 | 0.15 | |
| P | 0.285 | 0.707 | 0.230 | |||
| MSEOunstable duration (sec) | IG | 10 (4 – 30) | 30 (5 – 30) | 11 (8 – 17) | 0.001 | 0.80 |
| CG | 30 (4 – 30) | 30 (5 – 30) | 0 (0 – 5) | 0.223 | 0.30 | |
| P | 0.011 | 0.845 | 0.000 | |||
| Jumping performance | ||||||
| Pmax_jump (W/kg) | IG | 23 (15 – 42) | 23 (15 – 42) | 0.3 (-0.9 – 1.6) | 0.569 | 0.14 |
| CG | 28 (16 – 48) | 29 (18 – 49) | 1.3 (0.2 – 2.2) | 0.044 | 0.50 | |
| P | 0.019 | 0.058 | 0.539 | |||
| Jumping height (cm) | IG | 21 (13 – 46) | 22 (13 – 42) | 1 (-0.4 – 3.2) | 0.127 | 0.38 |
| CG | 29 (10 – 45) | 28 (17 – 47) | 2 (0.5 – 3.5) | 0.017 | 0.59 | |
| P | 0.045 | 0.068 | 0.838 | |||
| Vibrations sense (scale 0–8) | ||||||
| First metacarpophalangeal joint | IG | 2.5 (0.0 – 7.5) | 3.4 (0.0 – 8.0) | 0.4 (-0.3 – 1.3) | 0.139 | 0.36 |
| CG | 4.0 (0.0 – 7.8) | 4.5 (0.5 – 6.6) | 0.4 (-0.1 – 0.9) | 0.083 | 0.40 | |
| P | 0.071 | 0.111 | 0.950 | |||
| Knuckle | IG | 3.8 (0.0 – 7.3) | 4.1 (0.0 – 8.0) | 0.0 (-1.1 – 0.9) | 0.977 | 0.01 |
| CG | 4.9 (0.0 – 7.0) | 5.4 (0.0 – 7.0) | 0.8 (0.3 – 1.3) | 0.017 | 0.55 | |
| P | 0.471 | 0.049 | 0.175 | |||
| Patella | IG | 5.0 (0.0 – 8.0) | 4.3 (0.0 – 7.3) | -0.8 (-2.0 – 0.0) | 0.041 | 0.50 |
| CG | 4.8 (0.0 – 6.5) | 5.6 (0.8 – 7.0) | 1.0 (0.4 – 1.6) | 0.002 | 0.71 | |
| P | 0.196 | 0.005 | 0.000 | |||
| Quality of life (%) | ||||||
| Global QoL | IG | 63 (17 – 100) | 79 (33 – 100) | 8 (-4 – 17) | 0.082 | 0.39 |
| CG | 67 (17 – 100) | 67 (50 – 100) | 4 (-4 – 13) | 0.307 | 0.23 | |
| P | 0.845 | 0.221 | 0.461 | |||
| Subjective CIPN symptoms | ||||||
| CIPN20 sum score# | IG | 28 (6 – 85) | 20 (9 – 69) | -10 (-17 – -4) | 0.007 | 0.65 |
| CG | 28 (4 – 70) | 24 (4 – 63) | -6 (-11 – -1) | 0.027 | 0.52 | |
| P | 0.782 | 0.499 | 0.257 | |||
| CIPN20 sensory score# | IG | 41 (4 – 85) | 26 (4 – 74) | -7 (-15 – 0) | 0.028 | 0.53 |
| CG | 38 (7 – 74) | 30 (7 – 70) | -7 (-15 – 0) | 0.018 | 0.56 | |
| P | 0.935 | 1.000 | 0.925 | |||
| CIPN20 motor score# | IG | 25 (0 – 79) | 8 (0 – 63) | -8 (-18 – 0) | 0.006 | 0.67 |
| CG | 17 (0 – 71) | 13 (0 – 62) | -2 (-6 – 2) | 0.278 | 0.26 | |
| P | 0.546 | 0.916 | 0.114 | |||
| CIPN20 autonomic score# | IG | 17 (0 – 83) | 0 (0 – 50) | -8 (-17 – 0) | 0.006 | 0.65 |
| CG | 14 (0 – 83) | 17 (0 – 33) | -6 (-17 – 0) | 0.151 | 0.34 | |
| P | 0.791 | 0.118 | 0.313 | |||
| CIPN20 upper extremity score# | IG | 19 (0 – 91) | 14 (0 – 81) | -7 (-14 – 2) | 0.063 | 0.45 |
| CG | 19 (0 – 71) | 19 (0 – 62) | -3 (-7 – 1) | 0.059 | 0.45 | |
| P | 0.961 | 0.641 | 0.616 | |||
| CIPN20 lower extremity score# | IG | 33 (8 – 96) | 25 (0 – 79) | -13 (-19 – -4) | 0.007 | 0.66 |
| CG | 29 (8 – 75) | 25 (8 – 71) | -8 (-15 – -2) | 0.014 | 0.58 | |
| P | 0.503 | 0.964 | 0.552 | |||
| NtxS score† | IG | 29 (11 – 40) | 32 (15 – 41) | 3 (1 – 6) | 0.015 | 0.59 |
| CG | 31 (16 – 39) | 31 (19 – 40) | 2 (0 – 4) | 0.064 | 0.42 | |
| P | 0.620 | 0.940 | 0.361 | |||
| Cardiorespiratory fitness | ||||||
| V̇O2peak (mL·min−1·kg−1) | IG | 21 (16 – 35) | 23 (17 – 33) | 0.2 (-1.7 – 1.7) | 0.650 | 0.15 |
| CG | 23 (17 – 54) | 25 (16 – 54) | 1.4 (-0.4 – 3.5) | 0.133 | 0.35 | |
| P | 0.369 | 0.242 | 0.417 | |||
| Pmax_CPET (W/kg) | IG | 1.4 (0.9 – 2.4) | 1.5 (0.8 – 2.4) | 0.1 (0.0 – 0.2) | 0.025 | 0.53 |
| CG | 1.6 (0.9 – 3.4) | 1.7 (0.9 – 3.5) | 0.1 (0.0 – 0.2) | 0.004 | 0.66 | |
| P | 0.408 | 0.245 | 0.443 | |||
| IAT (W/kg) | IG | 1.1 (0.6 – 2.0) | 1.1 (0.6 – 1.8) | 0.1 (-0.2 – 0.1) | 0.122 | 0.36 |
| CG | 1.1 (0.5 – 2.6) | 1.3 (0.8 – 2.6) | 0.1 (0.0 – 0.1) | 0.020 | 0.54 | |
| P | 0.374 | 0.358 | 0.707 | |||
Notes: * prescribes the treatment effect by point estimation and 95% confidence interval of the Hodges-Lehmann’s median differences for paired groups; # scoring from 0 (no symptoms) – 100 (severe symptoms); † scoring from 0 (severe symptoms) – 44 (no symptoms); bold type indicates significance P<0.05
Abbreviations: T0 pre intervention, T1 post intervention, CI confidence interval, P p-value, rϕ Phi coefficient, STEO/ EC semi-tandem stance with eyes open/closed, MSEO/EOunstable Monopedal stance with eyes open on unstable surface, Pmax_jump/CEPT maximum power output during jumping/CEPT, CEPT cardiopulmonary exercise test, QoL quality of life, CIPN20 module of the EORTC-QLQ (European Organization for Research and Treatment of Cancer Quality of Life) questionnaire, NtxS neurotoxicity subscale of FACT/GOG (Functional Assessment of Cancer Therapy/Gynaecology Oncology Group), V̇O2peak peak oxygen consumption, IAT individual anaerobic threshold, IG interventions group, CG control group